Non Hodgkin Lymphoma Clinical Trial

Clinical Trial Finder Non Hodgkin Lymphoma Trials

Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma

See Locations Near You

Summary

The purpose of this study is to evaluate the effect of the combined treatment of lenalidomide and rituximab in controlling the Follicular Lymphoma disease and also increase the length of response compared to the available standard combination chemotherapy treatment for Follicular Lymphoma.

View Full Description

Full Description

Follicular Lymphoma (FL) is a cancer of a B lymphocyte, a type of white blood cell. FL is typically a slowly progressing but incurable disease. Follicular lymphoma cells produce a specific defect in the patient's immune system impairing their ability to control their cancer. Lenalidomide has been shown to reverse the specific immune defect caused by FL in the patient. By including lenalidomide, the RELEVANCE study aims to eliminate the cancer while restoring the patient's immune competence.

The 'Relevance' cooperative group trial is being conducted as two companion studies: RV-FOL-GELARC-0683 (N=750) and RV-FOL-GELARC-0683C (N=250); the combined total of 1000 Follicular Lymphoma patients enrolled in both studies will be analyzed.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Histologically confirmed follicular lymphoma grade 1, 2 or 3a, Stage II-IV
Have no prior systemic treatment for lymphoma
Symptomatic follicular lymphoma requiring treatment.
Age ≥18 years
Eastern Cooperative oncology group performance status 0-2
Willing to follow pregnancy precautions

Exclusion Criteria:

Clinical evidence of transformed lymphoma or Grade 3b follicular lymphoma.
Major surgery (excluding lymph node biopsy) within 28 days prior to signing informed consent.
Known seropositive for or active viral infection with hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV)
Known sensitivity or allergy to murine products.
Presence or history of central nervous system involvement by lymphoma
At high risk for a venous thromboembolic event (VTE) and not willing to take VTE prophylaxis
Any of the following laboratory abnormalities:
serum aspartate transaminase or alanine transaminase > 3x upper limit of normal (ULN), except in patients with documented liver involvement by lymphoma
total bilirubin > 2.0 mg/dl (34 µmol/L) except in cases of Gilberts Syndrome and documented liver or pancreatic involvement by lymphoma
creatinine clearance of < 30 mL/min

Study is for people with:

Non Hodgkin Lymphoma

Phase:

Phase 3

Estimated Enrollment:

255

Study ID:

NCT01476787

Recruitment Status:

Active, not recruiting

Sponsor:

Celgene

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 47 Locations for this study

See Locations Near You

Ironwood Cancer and Research Center
Chandler Arizona, 85224, United States
Providence St Joseph Medical Center Cancer Center
Burbank California, 91505, United States
Compassionate Cancer Care Medical Group
Corona California, 92829, United States
Lalita Pandit, MD Inc.
Fountain Valley California, 92708, United States
Saint Jude Heritage Medical Center
Fullerton California, 92835, United States
Santa Monica Hematology Oncology
Los Angeles California, 90095, United States
Memorial Hospital
Colorado Springs Colorado, 80909, United States
Cancer Center of Central Connecticut
Southington Connecticut, 06489, United States
University Cancer Institute
Boynton Beach Florida, 33426, United States
Florida Cancer Specialists
Englewood Florida, 34223, United States
Holy Cross Hospital
Fort Lauderdale Florida, 33308, United States
Orlando Health, Inc
Orlando Florida, 32806, United States
Florida Cancer Specialists
Saint Petersburg Florida, 33705, United States
Advocate Illinois Masonic Medical Center
Chicago Illinois, 60657, United States
Kentucky Cancer Clinic
Hazard Kentucky, 41701, United States
University of Kentucky
Lexington Kentucky, 40536, United States
Ochsner Clinic Foundation
New Orleans Louisiana, 70121, United States
Saint Joseph Medical Center
Westminster Maryland, 21157, United States
Mass General Hospital
Boston Massachusetts, 02114, United States
Newland Medical Associates, PC
Southfield Michigan, 48075, United States
Washington University School of Medicine
Saint Louis Missouri, 63110, United States
University of Nebraska Medical Center
Omaha Nebraska, 68198, United States
The Cancer Center at Hackensack University Medical Center
Cherry Hill New Jersey, 08003, United States
The Cancer Center at Hackensack University Medical Center
Hackensack New Jersey, 07601, United States
Hematology Oncology Associates of NJ
Morristown New Jersey, 07960, United States
Somerset Hematology-Oncology Associates
Somerset New Jersey, 08873, United States
The Cancer Center at Hackensack University Medical Center
Sparta New Jersey, 07871, United States
St. Luke's Roosevelt Hospital
New York New York, 10019, United States
Memorial Sloan-Kettering Cancer Center
New York New York, 10021, United States
Roger Maris Cancer Center
Fargo North Dakota, 58122, United States
Sarah Cannon Cancer Center
Nashville Tennessee, 37203, United States
Baylor Sammons Cancer Center
Dallas Texas, 75246, United States
MD Anderson Cancer Center
Houston Texas, 77030, United States
Joe Arrington Cancer Center
Lubbock Texas, 79410, United States
Virginia Cancer Institute
Richmond Virginia, 23230, United States
Seattle Cancer Care Alliance
Seattle Washington, 98109, United States
National Cancer Center Hospital
Chuo-ku , 104-0, Japan
Kyushu University Hospital
Higashi-ku, Fukuoka , 812-8, Japan
Chugoku Central Hospital
Hiroshima , 72000, Japan
Kobe City Medical Center General Hospital
Hyogo , 650-0, Japan
Tokai University School of Medicine
Isehara City, Kanagawa , 259-1, Japan
The Cancer Institute Hospital of Japanese Foundation For Cancer Research
Koto-ku , 135-8, Japan
University Hospital, Kyoto Prefectural University of Medicine
Kyoto-city , 602-8, Japan
Toranomon Hospital
Minato-ku , 105-8, Japan
Kurashiki Central Hospital
Okayama , 710-8, Japan
Sendai Medical Center
Sendai-city , 983-8, Japan
Juntendo University Shizuoka Hospital
Shizuoka , 410-2, Japan
Load More

How clear is this clinincal trial information?

Study is for people with:

Non Hodgkin Lymphoma

Phase:

Phase 3

Estimated Enrollment:

255

Study ID:

NCT01476787

Recruitment Status:

Active, not recruiting

Sponsor:


Celgene

How clear is this clinincal trial information?

Clinical Trial Resources

Why I’d Choose a Clinical Trial For Myself
Clinical Trials Can be Life-Saving for Some
Clinical Trials Test State-of-the-Art Cancer Treatments
×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider